Modality
Vaccine
MOA
Cl18.2
Target
PRMT5
Pathway
RNA Splicing
MCCT2DOCD
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
~Jun 2020
→ ~Sep 2021
NDA/BLA
Dec 2021
→ Dec 2028
NDA/BLACurrent
NCT04900433
2,126 pts·T2D
2021-12→2028-12·Recruiting
2,126 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-222.7y awayPh3 Readout· T2D
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2028-12-22 · 2.7y away
T2D
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04900433 | NDA/BLA | T2D | Recruiting | 2126 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 |